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Previous reports document expression of low-density lipoprotein receptor-related protein 5 (LRP5) in
osteosarcoma (OS) tissue. Expression of this Wnt receptor correlated with metastatic disease and poor
disease-free survival. Forced expression of dominant-negative LRP5 (dnLRP5), which lacks the membrane binding
domain of the native protein and therefore functions as a soluble receptor-sponge for Wnt ligands, reduced in vitro
cellular invasion and in vivo xenograft tumor growth for osteosarcoma cell lines. Here, we use a genetically
engineered mouse model of osteosarcomagenesis with and without expression of dnLRP5 to assess to what
degree tumorigenesis is affected and whether Wnt/β-catenin signaling is circumvented or maintained. Each cohort
of mice developed osteosarcoma at a similar ultimate prevalence, but after a slightly increased latency in those
also expressing dnLRP5. On histology, there was no difference between groups, despite previous reports that the
dnLRP5 osteosarcoma cells specifically undergo a mesenchymal-to-epithelial transition in vitro. Finally,
immunohistochemistry showed the presence of cytosolic and nuclear β-catenin and nuclear Cyclin D1, markers
consistent with preserved Wnt/β-catenin signaling despite constitutive blockade of the cell surface receipt of Wnt
signaling ligand. These data suggest that canonical Wnt signaling plays a role in OS progression and that while
blockade of singular nodes in signaling pathways can have dramatic effects on individual cell lines, real tumors
readily evade such focused attacks.
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The most common primary bone malignancy, osteosarcoma (OS)
remains a leading cause of cancer death in adolescents and young
adults [1]. Current treatment paradigms, which have not changed in
30 years, achieve little better than 50% long-term survival. There
remains a great need to understand the underlying mechanisms of
tumor progression before more targeted therapies may be realized.
Wnt genes encode a family of highly conserved, secreted proteins,
modulating cell fate and cell proliferation during embryonic
deve lopment and oncogenes i s through act ivat ion of
receptor-mediated signaling pathways. Binding of Wnt ligands to
the cell surface receptors frizzled (FZD) and low-density lipoprotein
receptor related protein 5 (LRP5), leads to blockade of a cytoplasmic
complex consisting of axin 2 (AXIN2), adenomatous polyposis coli
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hypophosphorylation and stabilization of β-catenin. Cytosolic
accumulation and translocation of β-catenin to the nucleus enables
formation of complexes with the T-cell factor/lymphoid enhancer
factor (TCF/LEF) family of transcription factors to promote the
expression of Wnt-responsive genes including c-Myc, cyclin D1, and
matrix matalloproteinases [2–4].
Wnt signaling is essential for the differentiation of mature osteoblasts
and, consequently, endochondral and membranous bone formation
[5–7]. In OS, overexpression of numerous Wnt components including
Wnt ligands, FZD, and LRP receptors implicate aberrant Wnt/
β-catenin signaling in the development and progression ofOS. In 2004,
Hoang, et al. utilized reverse transcription polymerase chain reaction
(RT-PCR) in four OS cell lines. Of the Wnt related genes, Wnt1 and
Wnt3 were expressed in two and three out of four cells lines,
respectively. Additionally, various forms of FZD, in addition to LRP5,
were expressed by all cell lines [8]. In another study, Chen et al. detected
expression of multipleWnt ligands and receptors in two humanOS cell
lines. They also, by immunohistochemical staining of 44 human OS
samples, identified the presence ofWnt10b in 75%with a trend toward
decreased survival in these patients [9].
LRP5, a single-pass transmembrane protein, is required as a
co-receptor for canonical Wnt-mediated signaling [10]. Additionally,
LRP5 functions as a major regulator of bone homeostasis [11–13].
Human OS metastasis has been linked to LRP5 expression [8]. Loss
of LRP5 in transgenic mice markedly reduces mammary tumor
formation. In cell culture studies, blockade of LRP5 signaling
decreases tumorigenicity of prostate cancer PC-3 cells, and drives a
mesenchymal-to-epithelial transition in PC-3 and SaOS-2 cells.
Moreover, dominant-negative LRP5 (dnLRP5) caused considerable
inhibition of tumor growth, invasion, and metastasis in an in vivo
xenograft model wherein dnLRP5-transfected 143B cells were
injected into a nude mouse [14]. Based on these studies, LRP5 is
significantly involved in OS disease progression as reflected in the
tendency for tumors expressing this receptor to metastasize.
The interaction between LRP5 and Wnt is implicated in a variety
of human diseases such that the aberrant activation of the Wnt/
β-catenin pathway is closely associated with a variety of human
cancers, skeletal tissue perturbation, and OS [13,15]. The ultimate
outcome of Wnt signaling, however, is shaped by those genes whose
activity is controlled through β-catenin and TCF. To explore whether
dnLRP5 may significantly alter the forward-going process of
osteosarcomagenesis, we used a mouse model of OS driven by
conditional disruption of tumor suppressor genes.
Materials and Methods
Animals
All experiments were performed with the approval of the
institutional animal care and use committee and in accordance with
international legal and ethical codes. Mice bearing LoxP-flanked
conditional alleles of Rb1 and Trp53 were obtained from Jackson
Laboratories [16,17]. OsxCreERT2 animals were previously de-
scribed [18]. All animals were genotyped using published protocols.
TheHprt-CAGG-LSL-dnLRP5mice were generated by targeting the
mouseHprt locus in R1 embryonic stem cells with a vector containing a
CAGG promoter followed by the cDNA for the dnLRP5 gene
separated from the promoter by a floxed stop cassette containing the
neomycin resistance gene. After positive and negative selection, cloneswere screened by PCR for the full-length insertion. A targeted clone was
injected into blastocysts. Resultant chimeras were bred and progeny
checked for germline transmission via tail tip DNA genotyping.
Imaging
Radiographs were obtained of sedated mice using a Kodak
Carestream 4000 Pro Fx imaging machine (Carestream Health,
Inc., Rochester, NY, USA). Light microscopy was viewed and
digitally photomicrographed using an Olympus BX43 microscope
and DP26 camera (Olympus America, Center Valley, PA, USA).
Histology
Tissues were harvested post-mortem, fixed in 4% paraformalde-
hyde overnight, decalcified in 14% EDTA at pH 7.4 for two weeks at
4 degrees, and embedded in paraffin following serial dehydration in
ethanol. In addition to standard hematoxylin and eosin (H&E)
staining, immunohistochemistry for mouse β-catenin (1:50 dilution,
Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and Cyclin D1
(1:500 dilution, Santa Cruz Biotechnology) were also performed,
using IgG-horse radish peroxidase goat anti-rabbit secondary (1:5000
dilution, sc-2004, Santa Cruz Biotechnology) and counterstained
with hematoxylin. All pathology was performed blinded to the sample
genotype.
Samples were considered positive if cytoplasmic or nuclear staining
was observed. Samples with isolated membrane staining or without
staining were considered negative. Stained sections were indepen-
dently examined by two investigators who were blinded to the
clinicopathologic data and LRP5 status of the all samples.
Immunohistochemical positivity was scored such that the relevant
staining pattern was defined (nuclear or cytoplasmic) followed by
applying a systematic random sampling approach for selection of
twenty-five separate fields of vision at 20X magnification [19]. In the
fields of vision, the percentage of positive cells was assessed followed
by grading and scoring positivity of cells as follows: negative (score 0),
weakly positive (score 1), positive (score 2), strongly positive (score 3),
and very strongly positive (score 4). Each sample was compared to the
previously scored sample and, if needed, re-scored to minimize intra
observer variance among all samples. A total score was calculated for
each sample by averaging the percentage of positive cells and the
degree of positivity and subsequently multiplying the average scores.
PCR Detection
PCR was conducted to verify that successful cre-mediated excision
of the stop sequence between the CAGG promoter and the dnLRP5
coding sequence occurred, and was maintained throughout the
duration of the experiment. Primers were constructed flanking the
stop sequence. Tumor DNA was harvested from sacrificed mice using
a DNeasy kit. For a negative control, muscle and liver tissue was
harvested from Hprt-CAGG-LSL-dnLRP5 mice that had not been
exposed to Tamoxifen. GAPDH primers were used as a loading
control. PCR reactions contained 150 μg of DNA per well, and ran
for 32 cycles. With successful excision, an amplicon of 172 base pairs
was amplified, and visualized on polyacrylamide gel.
Results
Inducing Mouse Osteosarcomagenesis With or Without Wnt
Surface Blockade
Cre-LoxP conditional disruption of Trp53 and Rb1 has been
shown to drive efficient osteosarcomagenesis in genetically
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within the osteoblast lineage [20–22]. To generate a highly
penetrant control mouse model of OS, we crossed mice bearing
conditional alleles of Rb1 (Rb1 fl/fl) and Trp53 (Trp53
fl/fl), to mice
bearing the Osterix-CreERT transgene, a tamoxifen-inducible
Cre-recombinase expressed in osteoblast precursors. Osterix is a
bone-specific transcription factor required for osteoblast develop-
ment, and this Osterix-CreERT transgene expresses Cre recombi-
nase in a manner that follows that of endogenous Osterix [18,23].
To achieve osteoblast lineage-restricted deletion, the OsxCreERT
transgenic mouse was used to direct Cre expression to committed
osteoblast progenitors.
To this background model of genetically driven osteosarcomagen-
esis was added the conditional expression of dnLRP5. The cDNA for
dnLRP5 with a polyA tail was targeted to the Hprt locus on the
mouse X chromosome, and separated from a CAGG promoter with
floxed stop (Figure 1A). In the presence of Cre-recombinase that
conditionally disrupts Trp53 and Rb1, the stop sequence is excised,
bringing dnLRP5 into position to be highly expressed by the CAGG
promoter.Figure 1. The impact of conditional expression ofWnt cell surface sign
theconditional expression allele ofdnLRP5 targeted to theHprt locusas
of the experimental design. (C) Kaplan–Meier plot of the fraction of mi
dnLRP. (D) PCR gel image demonstrating the presence of the recom
conditional dnLRP5.Cell Surface Wnt Signaling Blockade Reduces But does not
Abrogate Osteosarcomagenesis
In order to test the relative tumorigenesis with or without blockade
of the cell surface receptor signaling of Wnt ligands, cohorts of mice
with homozygous Trp53 and Rb1 conditional disruption in
pre-osteoblasts with or without conditional activation of dnLRP5
expression were generated (Figure 1B). Male mice positive for
Hprt-CAGG-LSL-dnLRP5 and female mice homozygous for the allele
were used for the experimental group, due to the possibility of
X-chromosome inactivation of the targeted allele in half the female
cells of heterozygotes. Mice were injected with tamoxifen to enable
Cre-mediated recombination at age 4 weeks, and then monitored
closely for apparent tumorigenesis or morbidity. Any morbid mice
were euthanized and thoroughly checked by radiography and gross
dissection for skeletal tumors.
The cohort of mice conditionally expressing dnLRP5 had slightly
increased latency to tumorigenesis, compared to the controls lacking
this allele (Figure 1C). The ultimate prevalence of tumorigenesis was
very similar in both groups, suggesting that osteosarcomagenesis was
only slightly delayed, but not stopped by the expression of dnLRP5.aling blockade on osteosarcomagenesis. (A) Schematic representing
well as conditionally disrupted allelesof Trp53 andRb1. (B) Schematic
ce without OS in the presence (green line) or absence (black line) of
bined floxed stop amplicon in all but one of the tumors bearing
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developed in mice bearing conditional dnLRP5 alleles to verify
successful excision of the stop sequence between the CAGG promoter
and the dnLRP5 gene. Of the tumors selected for PCR testing, all but
one demonstrated the presence of the recombined (active) allele, as
shown by an amplicon of 172 bp.
Osteosarcomas Formed With or Without Cell Surface Wnt
Signaling are Indistinguishable
Radiographs of mice upon reaching morbidity demonstrated
tumors of similar appearance between the two groups. Mineralized
matrix-producing tumors that destroyed portions of the mouse
skeleton were identified almost universally in morbid mice lacking
conditional expression of dnLRP5. Tumors of an indistinguishable
appearance were identified in mice expressing conditional dnLRP5
(Figure 2A).
Histopathologic analysis of H&E stained cross sections of tumors
demonstrated a range of osteoblastic differentiation states among
tumors in both groups (Figure 2B). Each tumor from either group had
demonstrably malignant cells producing osteoid matrix somewhere
within the central cross section examined, confirming that all fit within
the standard diagnosis of osteosarcoma used clinically in humans.Figure 2. dnLRP5 expression does not change radiographic or histolo
of tibia-located osteosarcomas in mice of each genotype. Each rad
disruption and soft tissue expansion. (B) Representative photomicrog
dnLRP5 genotypes demonstrate hypercellularity, nuclear pleomorph
are 20 μm in length.)Downstream Wnt Signaling Remains Intact in Osteosarcomas
that have Escaped Cell Surface Signal Blockade
Mice conditionally expressing dnLRP5 demonstrated a slightly
longer latency to tumorigenesis, suggesting that blocked Wnt
signaling impeded osteosarcomagenesis. Immunohistochemistry was
used to determine if tumors that developed in spite of dnLRP5
expression arose from bypassing a need for canonical Wnt signaling or
from bypassing the cell surface receptor blockade itself. Sections from
tumors derived from dnLRP5-expressing and control osteosarcomas
were immunostained for β-catenin and Cyclin D1, a known Wnt/
β-catenin/TCF/LEF transcriptional target. When scored for each, the
two groups of tumors were indistinguishable with regard to staining
intensity (Figure 3). This suggests that the cell surface blockade and
not the downstream signaling itself is what cells overcame in the
process of transformation.
Blockade of Cell Surface Wnt Signaling does not Prevent
Metastasis in Osteosarcomagenesis
As noted above, prior work with cell lines suggested that expression
of dnLRP5 was sufficient to drive an epithelial cell morphology
associated with blunted invasiveness and reduced metastasis. In
contrast, the OSs that form via circumventing dnLRP5 retain clearlygic features of osteosarcomagenesis. (A) Radiographs of examples
iograph shows a large proximal tibia OS associated with osseous
raphs of H&E histopathology from tumors that arose in control and
ism, and a range of osteoid matrix production. (Magnification bars
Figure 3. Tumors retain downstream Wnt signaling despite dnLRP5 expression in osteosarcomagenesis. (A) Representative
immunohistochemical analysis of β-catenin in osteosarcoma tissue showing positively stained samples in control and dnLRP5 groups.
Both cytoplasmic (open arrows) and nuclear (black arrows) staining patterns are evident. (B) Graph demonstrating no difference in the
degree of β-catenin detected between groups. (C) Representative photomicrographs of immunohistochemical detection of Cyclin-D1 in
osteosarcoma samples in control and dnLRP5 tumors. (D) Graph demonstrating no difference in Cyclin-D1 expression between groups.
(Magnification bars are 20 μm in length.)
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widely varied morphology and nuclear pleomorphism, consistent
with a genetically unstable and aggressive malignancy, but nothing
that tended toward epithelial differentiation (Figure 4A). Further,
some of the dnLRP5 expressing mice developed clinically detectable
metastasis (Figure 4B).
Discussion
Although Wnt signaling in cancer has been extensively studied, its
role in osteosarcoma has only recently been investigated. In anFigure 4. No evidence of mesenchymal-to-epithelial transition in d
dnLRP5-expressing osteosarcoma sample demonstrating nuclear pleo
this notion, the radiograph (B) from a dnLRP5-expressing osteosarc
pulmonary (white arrows) metastases. (Width of photomicrograph posteosarcoma-producing mouse model, we have demonstrated that a
block to cell surface Wnt signaling by a soluble, dominant-negative
form of the LRP5 receptor impedes, but cannot abrogate
osteosarcomagenesis. Although tumors arose in the dnLRP5 group
after a slightly increased latency, they arose at a similar ultimate
prevalence compared to control animal tumors and had indistin-
guishable radiographic and histopathologic features. Our data further
shows that the osteosarcomas that developed in spite of the block to
cell surface Wnt signaling demonstrated preserved Wnt signaling at
the nucleus.nLRP5 expressing tumors. High power photomicrograph (A) of a
morphismwithout evidence of epithelial differentiation. In line with
oma mouse demonstrates evidence of hepatic (open arrows) and
anel in A is 40 μm.)
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important role in skeletal osteogenesis and sarcomatous transforma-
tion [8,12,13,15]. In human OS tissue samples, LRP5 mRNA has
been shown to correlate with increased metastatic disease and an
inferior disease-free survival. In their orthotopic OS metastasis model
in nude mice, Guo et al. showed that expression of dnLRP5 reduced
pulmonary metastasis and decreased cellular invasiveness of SaOS-2
cells in vitro [14,24].
Previous studies have suggested that blocking Wnt/β-catenin
signaling at the level of dnLRP5 in cell lines achieves an apparent
mesenchymal-to-epithelial transition. OS cell lines induced to express
dnLRP5 showed decreased expression of Pro-MM2, N-cadherin, and
Snail [14]. Based on our histological results however, there is no
evidence of such a morphologic cellular transition when the tumor
develops in spite of cell surface Wnt blockade. The multiplicity of
pathways driving mesenchymal differentiation in OSs may not be so
readily overturned with inactivation of this pathway from the onset of
transformation.
To initiate Wnt/β-catenin signaling, Wnt ligands bind the Frizzled
receptor. LRP5 is an identified co-receptor required for transducing
extracellular Wnt signaling into an intracellular response [10].
Importantly, the tumors that developed in our osteosarcomagenesis
model with blocked cell surface Wnt by dnLRP5 expression did not
demonstrate blocked downstream Wnt signaling. They showed
similar levels of cytosolic and nuclear β-catenin, and nuclear cyclin
D1, by immunohistochemistry in comparison to control tumors
lacking dnLRP5. This suggests that tumors have circumvented the
cell surface block to Wnt signaling, but not Wnt signaling itself.
Our efforts did not provide the molecular mechanism by which
dnLRP5 is circumvented in each tumor, only that it was
circumvented, and not merely not recombined into the active allele
state in most tumors. The single tumor that displayed no amplified
recombined sequence may have developed from a cell that
recombined the other alleles, but not the Hprt allele. Alternatively,
during progression, the tumor cells may have cytogenetically lost the
Hprt locus altogether. Otherwise, recombined, active alleles were
present in all the other tumors assessed. The complexity of Wnt
extracellular and membrane components, which consist of at least 19
Wnts, 10 Frizzled receptors, and co-receptors LRP5 and 6, suggest a
panoply of escape routes around the blockade by dnLRP5. The
tumors may have arisen in a subset of pre-osteoblasts with already
upregulated internal Wnt signaling. They may have inactivated the
dnLRP5 allele or abundantly up-regulated autocrine Wnt signals. It is
also conceivable that transforming cells faced with constitutional
blockade of the initiating Wnt/β-catenin signal developed genetic
mutations or copy number changes that inactivated the β-catenin
destruction complex.
Conclusions
Our data suggest intrinsic difficulty in abrogating Wnt signaling via
cell surface blockade. Previous experiments in cell lines reported that
dnLRP5 mediated a profound suppressive effect on tumor growth
and invasiveness. Added to the heterogeneity of osteosarcomagenesis
instead, dnLRP5 failed to block OS formation, metastatic disease, and
even maintenance of Wnt signaling. Osteosarcomagenesis is likely an
adaptive and aggressive transformation process that can overcome
blockade of any single node in a complex pathway.
In summary, we demonstrate that OS progression is not inhibited
in an in vivo model of cell surface Wnt/β-catenin blockade.Additionally, Wnt signaling is maintained resulting in stabilized
β-catenin enabling downstream TCF/LEF mediated expression of
Wnt-responsive genes.
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